Medimaps Group - creators of TBS Osteo powered by TBS iNsight ™ - medical AI technology.

Medimaps Group is a leading global medical software analytics company founded by a group of clinical practitioners and researchers, based in Switzerland with offices in the US and in France. It specializes in the engineering, research, development, and commercialization of medical software applications based on patented multi-purpose technologies. Its flagship product, the TBS iNsight™ (Osteo) software application has been used for years in over 75 countries in clinical practice to better predict fracture risk in the field of primary and secondary osteoporosis (e.g. in patients with diabetes, hyperparathyroidism, CKD, HIV, and GIO). The maximal impact of the TBS score is observed in patients with osteopenic BMD values who display low TBS scores and consequently have a higher combined risk profile; in patients whose fracture risk is close to the FRAX ® intervention thresholds; and in secondary osteoporosis. While BMD is often limited to identify patients with secondary OP who are at risk for fractures, TBS can be used as an aid in the diagnosis of osteoporosis and other medical conditions leading to altered trabecular bone microarchitecture. TBS Osteo has become the gold standard for bone structure assessment in routine clinical practice, with over 1500 scientific publications, and mentioned in over 30 national and international guidelines (e.g. ISCD, ESCEO, DVO, NOGG). Ultimately, the combination of TBS™ , BMD and clinical risk factors or FRAX® can help you: • IDENTIFY patients that were wrongly categorized in terms of risk fracture ; • FINE-TUNE therapy decisions • IMPROVE patient management in clinical routine. This core technology has been further developed, and new medical applications have been created in the dental and orthopedics fields. Medimaps is also exploring applications in veterinary medicine and oncology. #TBSiNsight #BoneQuality #BMD #TScore #Osteoporosis #BoneStructure #UseBMDandTBS #Fracture #DXA #AI